Adverse Event reporting information can be found in footer

Request a Meeting

MANAGING MICROSCOPIC COLITIS

NatSteroidAudit-SideImage-1

 

 

 

DIAGNOSING MICROSCOPIC COLITIS:

 

  • A complete medical history and physical examination can help determine whether other conditions, such as celiac disease, may be contributing to the diarrhoea3
  • Colonoscopy, intestinal issues often appear normal in microscopic colitis3
  • Stool sample analysis to help rule out infection as the cause of persistent diarrhoea3
  • Blood test to look for signs of anaemia or infection3

 

 

ACCURATE DIAGNOSIS OF MICROSCOPIC COLITIS IS ESSENTIAL FOR APPROPRIATE TREATMENT4

 

RULE OUT IRRITABLE BOWEL SYNDROME THROUGH CLINICAL HISTORY4

Approximately 33-50% of patients who present with Microscopic Colitis meet symptom criteria for irritable bowel syndrome (IBS), often resulting in misdiagnosis.4

 

However, in most cases, by taking a thorough clinical history and using a bowel diary for 1-2 weeks, it is possible to distinguish between IBS and Microscopic Colitis.4

 

 

PATIENTS WITH MC HAVE A CLINICAL HISTORY THAT IS USUALLY DISTINCT FROM THAT OF PATIENTS WITH IBS4

Clinical history variable Irritable bowel syndrome Microscopic Colitis
First occurrence of disease Usually before 50 years of age Usually after 50 years of age
Stool consistency Soft-variable-hard Watery/soft
Abdominal pain/discomfort Obligatory Variable
Nocturnal diarrhoea Very unlikely Possible
Feeling of complete bowel evacuation Common No
Weight loss Rare Common
Faecal incontinence Rare Common
Feeling of fullness/bloating Common Rare
Accompanying autoimmune disease Rare Common

 

 

 

EUROPEAN MICROSCOPIC COLITIS TREATMENT GUIDELINES RECOMMEND BUDESONIDE 9 MG/DAY FOR 6 TO 8 WEEKS1

 

 

These recently published guidelines provide information on epidemiology and risk factors of microscopic colitis, as well as evidence-based statements and recommendations on diagnostic criteria and treatment options, including oral budesonide, bile acid binders, immunomodulators and biologics. Recommendations on the clinical management of microscopic colitis are provided based on evidence, expert opinion and best clinical practice1

 

 

No CORTIMENT dose tapering required2

 

 

  • Miehlke S, et al. United European Gastroenterol J. 2020;0(0):1–28.
  • Cortiment 9 mg, Prolonged Release Tablets. SmPC.
  • Microscopic Colitis / IBD Clinic (Accessed 7 April 2021)
  • Münch A, et al. Frontline Gastroenterology. 2020;11:228-234.

Job Code: UK-COR-2200001 - Date of preparation: January 2022

cookiepopup

Our use of cookies

We use cookies (including third party cookies) to collect data while you use this website in order to make it work, keep it secure and comply with regulations. We’d also like your consent to use cookies so we can provide you with tailored content and advertising and analyse how you and other people use the website.

Select “On” to consent to our use of these cookies and continue to the website, or select “Off” to control which types of cookies we use. You can read more about cookies in our Privacy Policy.

Necessary cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytics cookies

We’d like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. The cookies collect information in away that does not directly identify anyone. For more information on how these cookies work, please see our Privacy Policy.